Company news
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) news
Metagenomi Therapeutics, Inc. news releases on 6ix. Latest, Sep 1, 2026: Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare…
Press releases & updates
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
September 1, 2026
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 10, 2026
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
May 28, 2026
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 11, 2026
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
April 15, 2026
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
March 4, 2026
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
February 23, 2026
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 12, 2026
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
December 1, 2025
Metagenomi to Present at Jefferies Global Healthcare Conference in London
November 17, 2025
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
November 11, 2025
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
November 11, 2025
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
August 12, 2025
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
August 11, 2025
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
May 14, 2025
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
May 13, 2025
Metagenomi to Present at Upcoming Scientific Meetings
May 2, 2025
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
March 17, 2025
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
March 13, 2025
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
January 15, 2025
Metagenomi Announces New Appointment to its Board of Directors
January 14, 2025
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
December 8, 2024
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
November 12, 2024
Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting
November 4, 2024
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
September 2, 2024
Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference
August 28, 2024
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
March 26, 2024
Metagenomi Announces Closing of Initial Public Offering
February 12, 2024